Clinical trial • Not applicable • Musculoskeletal

HUMAN CANCELLOUS BONE for Meniscus tear | Meniscus injury

Not applicable trial of HUMAN CANCELLOUS BONE for Meniscus tear | Meniscus injury.

Overview

Trial Therapeutic Area
Musculoskeletal
Trial Disease
Meniscus tear | Meniscus injury
Trial Stage
Not applicable
Drug Modality
Other

Key dates

Initial CTIS Submission Date
23-09-2023
First CTIS Authorization Date
15-03-2024

Trial design

open-label, non-operated group (patients who decide not to undergo surgery) — observational comparator (no drug comparator specified).-controlled Not applicable trial across 1 site in Germany.

Open Label
Yes
Comparator
Non-operated group (patients who decide not to undergo surgery) — observational comparator (no drug comparator specified).
Real World Control
Yes
Target Sample Size
30
Trial Duration For Participant
1825

Eligibility

Recruits 30 Vulnerable populations are not selected for this trial. Participants must be adults aged 18-60 years. Written informed consent is required from each participant (no assent process described)..

Pregnancy Exclusion
pregnancy (only for patients with surgery)
Vulnerable Population
Vulnerable populations are not selected for this trial. Participants must be adults aged 18-60 years. Written informed consent is required from each participant (no assent process described).

Inclusion criteria

  • {"criterion_text":"- Partial loss of portions of the lateral meniscus and lateral joint line pain OR - Partial loss of the medial meniscus and medial joint line pain\n- Age 18-60 years\n- written consent to the study and to provide the scientific data in pseudonymized form\n- sufficient standing of the peripheral rim, so that the procedure can be performed"}

Exclusion criteria

  • {"criterion_text":"- Presence of anterior cruciate ligament insufficiency that is not resolved by reconstruction of the anterior cruciate ligament within 16 weeks after partial meniscal implantation.\n- Chronic pain patients\n- inflammatory arthritis or synovitis on the treated knee\n- only for patients who will be operated: - with increased anesthesiological risk, e.g. with known or predicted difficult airway - with increased risk of bleeding - with increased risk of infection - with necrotic, infected or poorly perfused host sides - history of allergic reactions or acute hypersensitivity reactions to the IMP or any of its excipients - pregnant woman\n- Axial deviation (>2° varus or valgus)\n- realignment osteotomy not performed within 12 weeks\n- advanced cartilage damage (grade III according to ICRS) and osteoarthrosis in the affected compartment (grade III according to Kellgren and Lawrence (Kellgren and Lawrence, 1957)\n- Extension deficit of more than 3° compared to the opposite side or a knee flexion of less than 125°\n- BMI greater than 30 kg/m²\n- <18 years, >60 years\n- pregnancy (only for patients with surgery)"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Improvement of PROMs (KOOS, IKDC, VAS Pain Score) 2 and 5 years after surgery compared to scores of the non-operated group and compared to pre-surgery scores.","definition_or_measurement_approach":"Measured using patient-reported outcome measures (PROMs): IKDC, KOOS, and VAS pain score; comparison between operated and non-operated groups and comparison to pre-surgery scores at 2 and 5 years."}

Secondary endpoints

  • {"endpoint_text":"- Safety of the patient: Type, frequency and severity of treatment-related AEs and SAEs","definition_or_measurement_approach":"Assessment of adverse events and serious adverse events by type, frequency and severity related to treatment."}
  • {"endpoint_text":"- Efficacy of the procedure: How many patients show a progression of osteoarthrosis up to TKA?","definition_or_measurement_approach":"Number/proportion of patients progressing to osteoarthrosis requiring total knee arthroplasty (TKA) over follow-up."}
  • {"endpoint_text":"- MRI evaluation: Outerbridge graduation, size of meniscus, number of patients with extrusion, size of extrusion after 6 weeks, 6 and 12 months (for operated patients) and after 2 and 5 years, comparison between the operated and the non-operated group","definition_or_measurement_approach":"MRI assessments including Outerbridge grading, meniscus size, presence and size of extrusion at specified timepoints (6 weeks, 6 and 12 months, 2 and 5 years) with operated vs non-operated group comparisons."}
  • {"endpoint_text":"- Patient satisfaction: very pleased, pleased, not pleased, very unsatisfied in the operated group after 2 and 5 years","definition_or_measurement_approach":"Patient-reported satisfaction categories collected in the operated group at 2 and 5 years."}

Recruitment

Planned Sample Size
30
Recruitment Window Months
84
Consent Approach
Written informed consent required from each participant. Subject information and informed consent form available (document: Aufklarung_mit_Datenschutz_Version_4_CT_2024_03_11). Participants are adults (18-60); no assent described.

Geography

Total Number Of Sites
1
Total Number Of Participants
30

Germany

Earliest CTIS Part Ii Submission Date
11-03-2024
Latest Decision Or Authorization Date
04-04-2025
Processing Time Days
389
Number Of Sites
1
Number Of Participants
30

Sites

Site Name
Dr. Sven Behrendt, Praxis für Knie und Schulterchirugie
Department Name
Praxis für Knie und Schulterchirugie
Principal Investigator Name
Sven Behrendt
Principal Investigator Email
s.behrendt@dokom.net
Contact Person Name
Sven Behrendt
Contact Person Email
s.behrendt@dokom.net
Number Of Participants
30

Sponsor

Primary sponsor

Full Name
Dr. Sven Behrendt, Knie und Schulterchirurgie
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
HUMAN CANCELLOUS BONE
Active Substance
HUMAN CANCELLOUS BONE
Modality
Other
Routes Of Administration
UNKNOWN USE
Route
UNKNOWN USE
Authorisation Status
No marketing authorisation (marketingAuthNumber: -)
Maximum Dose
1 U unit(s)

Related trials

Other published trials that may interest you.